AI-generated summary
This protocol describes a planned randomised, double-blind trial comparing amber photobiomodulation at 590 nm with liposomal tranexamic acid for facial melasma in 54 women. The authors report that results have not yet been obtained, so no efficacy finding is available from this paper.
- Participants
- 54
- Who or what was studied
- Women aged 35-50 years with facial melasma and skin phototypes II-IV, planned for 54 participants at two centres in Sao Paulo State, Brazil.
- Wavelengths
- 590 nm
- Limits stated in the abstract
- This is a study protocol only, so no outcome data are reported, and the abstract does not describe any results.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmjopen.bmj.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 590 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Intention-to-treat analysis, Trial registration, Primary outcome, Melanin, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.